Cure Alzheimer's Fund Cure Alzheimer's Fund

Support of Cerebrospinal Fluid Biomarker Study–ADNI

2007

Cure Alzheimer’s Fund is part of a funding consortium supporting collaborative biomarker investigation of the elevation of tau and decreased concentrations of Amyloid beta 42 in the cerebrospinal fluid (CSF) as evidence of the presence of the Alzheimer’s disease pathology.

Biomarkers/Diagnostics/Studies of Risk & Resilience Foundational John Q. Trojanowski Leslie M. Shaw

Funding to Date

$100,000

Focus

Biomarkers/Diagnostics/Studies of Risk & Resilience, Foundational

Researchers

John Q. Trojanowski, M.D., Ph.D.

Leslie M. Shaw, Ph.D.

Related Content:


Bioinformatics Platform for Modeling Alzheimer’s Progression (MAP-AD Platform) Ali Ezzati 2024-09-16 Understanding Human Brain Resilience to Alzheimer’s Pathology Teresa Gomez-Isla 2024-08-19 Utility of Blood-Based Markers for Predicting Amyloid-Related Imaging Abnormalities and Their Course in Mild Cognitive Impairment and Alzheimer’s Disease Subjects Undergoing Routine Clinical Treatment with Amyloid-Directed Antibodies P. Murali Doraiswamy 2024-01-12 Characterization of the Longitudinal Trajectories of the Synaptic Blood Marker Beta-Synuclein during Alzheimer’s Disease Pathogenesis and Improvement of the Measurement Procedure Patrick Oeckl Markus Otto 2023-09-19 Precision Medicine Prediction Model for Alzheimer’s Disease Using Cooperative Learning Approaches for Multi-Omic Data Christoph Lange 2023-05-02 Adding Genomics and Methylomics to Personalized Disease Prediction for Alzheimer’s Disease (EPIC4AD) Lars Bertram Christina M. Lill 2023-02-28 Identification and Validation of Plasma-Based Lipid Biomarkers for Early Alzheimer’s Disease in the Unique, Primarily Hispanic, South Texas Population Xianlin Han Bernard Fongang Juan Pablo Palavicini Tiffany F. Kautz 2023-02-23 Cerebrospinal Fluid Neuroinflammatory Signature in Alzheimer´s Disease and Related Proteopathies Mathias Jucker Stefan Lichtenthaler Stephan Kaeser 2022-11-22